Seattle cell therapy + immuno-oncology
Seattle cell therapy insurance — Fred Hutch ecosystem, post-Juno and post-Seagen lineage.
Seattle's cell therapy and immuno-oncology cluster is one of the most concentrated specialty biotech ecosystems in the United States. Fred Hutchinson Cancer Center anchors the academic and clinical foundation. The post-Juno (Celgene/BMS acquisition) and post-Seagen (Pfizer acquisition) diaspora has populated the cluster with experienced cell therapy and ADC operators. Adaptive Biotechnologies anchors immune sequencing; Sana Biotechnology, Lyell Immunopharma, ArsenalBio, and a long tail of clinical-stage operators round out the cluster. Insurance programs in this cluster are at the leading edge of clinical trial liability for irreversible interventions, transactional D&O for IPO and SPAC-bound biotechs, and the cyber/HIPAA implications of Washington's My Health My Data Act (MHMDA).
Cluster characteristics
Cell therapy clinical trial liability is the dominant risk.
Cell and gene therapy first-in-human dosing carries clinical trial liability profile unlike any other category in drug development. The interventions are typically irreversible. Cytokine release syndrome, neurotoxicity, on-target/off-tumor toxicity, and immune effector cell- associated neurotoxicity syndrome (ICANS) drive a claim severity profile that conventional small-molecule clinical trial liability programs are not sized for. Sponsor-side limits commonly run $5M-$15M per trial for Phase 1 cell therapy programs, with extended-reporting-period coverage decisions through FDA-mandated long-term follow-up registries (10-15 years).
Late-stage clinical-stage biotechs in the cluster carry D&O sized to IPO or PIPE readiness. Transactional D&O structures (Side A DIC + B + C) at $25M-$100M with 7-year discovery periods are standard for IPO-bound programs; the 2023 SEC cyber disclosure rule has driven cyber liability program sizing into the $5M-$15M range for IPO-readiness reviews.
ADC (antibody-drug conjugate) programs in the post-Seagen lineage carry unique products liability and clinical trial liability considerations — payload-related toxicity, biomarker- selected patient populations, and the long pharmacovigilance tail on novel conjugation chemistries drive program structure decisions that don't exist for naked monoclonal antibody programs.
Washington regulatory + market context
MHMDA reshapes cyber liability for health-data handlers.
Washington's My Health My Data Act (MHMDA), effective 2024, extends consumer-health-data privacy obligations well beyond HIPAA. Where HIPAA applies only to covered entities and business associates, MHMDA applies to any entity that conducts business in Washington and collects consumer health data — a definition that captures digital health, AI healthtech, clinical research operators, and most biotech operators with patient-facing infrastructure. MHMDA includes a private right of action; cyber liability programs for Seattle operators handling consumer or patient health data should explicitly cover state-law claims alongside HIPAA breach response.
Washington's product-liability appellate posture is moderately plaintiff-friendly; the jurisdictional consideration matters most for sponsor MSAs that default to WA jurisdiction. The depth of specialty market access for Seattle operators is reasonable but smaller than the Cambridge or NJ corridor — specialty markets serving the cluster typically operate through wholesale broker relationships from San Francisco or NY/NJ.
Premium levels for Seattle cell therapy operators run roughly comparable to Cambridge and materially above Texas at comparable revenue — the combination of clinical trial liability severity, transactional D&O readiness for IPO-bound programs, and MHMDA cyber exposure drives the cost structure. Operators with strong FDA inspection records and clean clinical- hold history find competitive specialty appetite.
Free coverage review